OncoMatch/Clinical Trials/NCT06420973
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Is NCT06420973 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies RC48+carboplatin±bevacizumab for ovarian carcinoma.
Treatment: RC48+carboplatin±bevacizumab — The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: HER2 (ERBB2) expression (IHC 1+, 2+, or 3+) (IHC 1+, 2+, or 3+)
Local laboratory confirmed HER2 expression: IHC 1+, 2+, or 3+
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: HER2-targeted therapy
Previously not receiving targeted HER2 drug therapy (including monoclonal antibodies and ADC drugs)
Lab requirements
Blood counts
Adequate haematological function as defined by the protocol
Kidney function
Adequate renal function as defined by the protocol
Liver function
Adequate hepatic function as defined by the protocol
Adequate haematological, hepatic and renal functions defined by the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify